Cite
Baraliakos X, Heldmann F, van den Bosch F, et al. Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open. 2016;2(2):e000272doi: 10.1136/rmdopen-2016-000272.
Baraliakos, X., Heldmann, F., van den Bosch, F., Burmester, G., Gaston, H., van der Horst-Bruinsma, I. E., Krause, A., Schmidt, R., Schneider, M., Sieper, J., Andermann, B., van Tubergen, A., Witt, M., & Braun, J. (2016). Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD open, 2(2), e000272. https://doi.org/10.1136/rmdopen-2016-000272
Baraliakos, X, et al. "Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction." RMD open vol. 2,2 (2016): e000272. doi: https://doi.org/10.1136/rmdopen-2016-000272
Baraliakos X, Heldmann F, van den Bosch F, Burmester G, Gaston H, van der Horst-Bruinsma IE, Krause A, Schmidt R, Schneider M, Sieper J, Andermann B, van Tubergen A, Witt M, Braun J. Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction. RMD Open. 2016 Jul 19;2(2):e000272. doi: 10.1136/rmdopen-2016-000272. eCollection 2016. PMID: 27493791; PMCID: PMC4964174.
Copy
Download .nbib